Cargando…
Correction: Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/ Akt signaling pathway in gastric cancer
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843975/ https://www.ncbi.nlm.nih.gov/pubmed/36647144 http://dx.doi.org/10.1186/s13046-023-02593-5 |
| _version_ | 1784870518904586240 |
|---|---|
| author | Xu, Jiahui Liu, Deying Niu, Huilin Zhu, Guifang Xu, Yangwei Ye, Danli Li, Jian Zhang, Qingling |
| author_facet | Xu, Jiahui Liu, Deying Niu, Huilin Zhu, Guifang Xu, Yangwei Ye, Danli Li, Jian Zhang, Qingling |
| author_sort | Xu, Jiahui |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9843975 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98439752023-01-18 Correction: Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/ Akt signaling pathway in gastric cancer Xu, Jiahui Liu, Deying Niu, Huilin Zhu, Guifang Xu, Yangwei Ye, Danli Li, Jian Zhang, Qingling J Exp Clin Cancer Res Correction BioMed Central 2023-01-17 /pmc/articles/PMC9843975/ /pubmed/36647144 http://dx.doi.org/10.1186/s13046-023-02593-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Xu, Jiahui Liu, Deying Niu, Huilin Zhu, Guifang Xu, Yangwei Ye, Danli Li, Jian Zhang, Qingling Correction: Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/ Akt signaling pathway in gastric cancer |
| title | Correction: Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/ Akt signaling pathway in gastric cancer |
| title_full | Correction: Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/ Akt signaling pathway in gastric cancer |
| title_fullStr | Correction: Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/ Akt signaling pathway in gastric cancer |
| title_full_unstemmed | Correction: Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/ Akt signaling pathway in gastric cancer |
| title_short | Correction: Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/ Akt signaling pathway in gastric cancer |
| title_sort | correction: resveratrol reverses doxorubicin resistance by inhibiting epithelial-mesenchymal transition (emt) through modulating pten/ akt signaling pathway in gastric cancer |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843975/ https://www.ncbi.nlm.nih.gov/pubmed/36647144 http://dx.doi.org/10.1186/s13046-023-02593-5 |
| work_keys_str_mv | AT xujiahui correctionresveratrolreversesdoxorubicinresistancebyinhibitingepithelialmesenchymaltransitionemtthroughmodulatingptenaktsignalingpathwayingastriccancer AT liudeying correctionresveratrolreversesdoxorubicinresistancebyinhibitingepithelialmesenchymaltransitionemtthroughmodulatingptenaktsignalingpathwayingastriccancer AT niuhuilin correctionresveratrolreversesdoxorubicinresistancebyinhibitingepithelialmesenchymaltransitionemtthroughmodulatingptenaktsignalingpathwayingastriccancer AT zhuguifang correctionresveratrolreversesdoxorubicinresistancebyinhibitingepithelialmesenchymaltransitionemtthroughmodulatingptenaktsignalingpathwayingastriccancer AT xuyangwei correctionresveratrolreversesdoxorubicinresistancebyinhibitingepithelialmesenchymaltransitionemtthroughmodulatingptenaktsignalingpathwayingastriccancer AT yedanli correctionresveratrolreversesdoxorubicinresistancebyinhibitingepithelialmesenchymaltransitionemtthroughmodulatingptenaktsignalingpathwayingastriccancer AT lijian correctionresveratrolreversesdoxorubicinresistancebyinhibitingepithelialmesenchymaltransitionemtthroughmodulatingptenaktsignalingpathwayingastriccancer AT zhangqingling correctionresveratrolreversesdoxorubicinresistancebyinhibitingepithelialmesenchymaltransitionemtthroughmodulatingptenaktsignalingpathwayingastriccancer |